Connecting Pharmacology with Therapeutics Clive Roberts.

Slides:



Advertisements
Similar presentations
& the certified athletic trainer
Advertisements

Instant Clinical Pharmacology E.J. Begg
Warfarin, Insulin and Digoxin are the most Dangerous drugs in the elderly. Do we believe that?
Pages 645 to 724 Mechanisms of Drug Interaction Pharmacokinetic –Reduced rate and/or completeness of absorption –Altered bioavailabilty –Reduced.
Prescribing in Disease Clive Roberts. So what are drugs good at treating (or preventing)? Pain Inflammation Infection Fluid retention Heart problems High.
Pharmacology for Anesthesia I Introduction. What is a Drug?
Principles of Drug Use in the Elderly Alastair Stephens Sophie Rozwadowski.
Drugs Used During Pregnancy & Lactation
Patterns of Prescription Drug Use among Older Adults Arlene S. Bierman, MD, MS Ontario Women’s Health Council Chair in Women’s Health Centre for Research.
Pharmacotherapy in the Elderly Paola S. Timiras May, 2007.
Pharmacotherapy in the Elderly Judy Wong
Chapter 6 Drug Interactions 1.
Includes adults >65 years old Fastest growing population in US and in the majority of developed nations. 20% of hospitalizations for those >65 are due.
Pharmacology in the Elderly. Pharmacological Challenges in the Elderly  Pharmacokinetic changes  Pharmacodynamic changes  Multiple co-morbidities 
Mosby items and derived items © 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 25 Drug Interactions.
Yasar Kucukardali Professor, Internal Medicine Yeditepe University.
Factors Affecting Drug Activity Chapter 11 Pages
non steroidal anti inflammatory drugs
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 11 Drug Therapy in Geriatric Patients.
Dose Adjustment in Renal and Hepatic Disease
Caring for Older Adults Holistically, 4th Edition Chapter Nineteen Pharmacology and Its Significance for Older Adults.
© 2004 by Thomson Delmar Learning, a part of the Thomson Corporation. Fundamentals of Pharmacology for Veterinary Technicians Chapter 4 Pharmacokinetics.
Problems of Polypharmacy
Mrs X.X. Born 1941 Known severe Rheumatoid arthritis Revision of hip replacement Jan Cardiac arrest post-op Anticoagulated Transferred to community hospital.
CARBONIC ANHYDRASE INHIBITORS ACETAZOLAMIDE E It is a sulfonamide derivative. It is a sulfonamide derivative. noncompetitively but reversible inhibits.
Orientation to Pharmacology
Chapter 4 Pharmacokinetics Copyright © 2011 Delmar, Cengage Learning.
Pharmacokinetics of strong opioids Susan Addie Specialist palliative care pharmacist.
Prepared By MARIAM SALEH ALAMRO A Calcium Channel Blocker.
PHARMACOKINETICS Part 3.
BASIC PHARMACOLOGY 2 SAMUEL AGUAZIM(MD).
Drug Therapy in the Elderly
INTRODUCTION CLINICAL PHARMACOKINETICS
© Paradigm Publishing, Inc.1 Chapter 2 Basic Concepts of Pharmacology.
DRUG TREATMENT OF HEART FAILURE IN PATIENTS WITH CHRONIC RENAL DISEASE Presented by Ri.
Donepezil. Donepezil Generic name: Donepezil. Brand name: Aricept. Chemistry: Donepezil hydrochloride is a piperidine derivative. It is a white crystalline.
Foundation Knowledge and Skills
METABOLISME DEPARTMENT OF PHARMACOLOGY AND THERAPEUTIC UNIVERSITAS SUMATERA UTARA dr. Yunita Sari Pane.
DOSAGE ADJUSTMENT IN RENAL AND HEPATIC DISEASES Course Title : Biopharmaceutics and Pharmacokinetics – II Course Teacher : Zara Sheikh.
Basic Concepts of Pharmacology © Paradigm Publishing, Inc.
Copyright © 2016 by Elsevier, Inc. All rights reserved. Geropharmacology.
PHARMACOKINETICS ABSORPTION →DISTRIBUTION→METABOLISM→EXCRETION Chapter 26 – Fundamentals NUR 152 Denise Turner, MS-N.Ed, CCRN, RN.
Pharmacology I Session One Pharmacological Principles.
Pharmacology Phone Number: (203)
Factors Affecting Drug Activity
Toxicology Drug Poisioning.
Drug Therapy in Geriatric Patients
Understanding the Basics of Pharmacology
FACTORS AFFECTING DRUG ACTIVITY
Toxicology Drug Poisioning.
Factors affecting Drug Activity
PHARMACY TECHNICIAN CHAPTER NINETEEN.
Introduction; Scope of Pharmacology Routes of Drug Administration
Pharmacology KNH 413 Most Americans are not meeting RDA. Nutrient deficiencies worsen when medication is taken.
Pharmacology KNH 413 Most Americans are not meeting RDA. Nutrient deficiencies worsen when medication is taken.
Pharmacologic Principles – Chapter 2
Pharmacokinetics and Factors of Individual Variation
CTD Module 4: Non-Clinical Studies SPC Relevant Scientific information
Pharmacology KNH 413 Most Americans are not meeting RDA. Nutrient deficiencies worsen when medication is taken.
Basic Biopharmaceutics
Pharmacology KNH 413 Most Americans are not meeting RDA. Nutrient deficiencies worsen when medication is taken.
Pharmacology KNH 413 Most Americans are not meeting RDA. Nutrient deficiencies worsen when medication is taken.
Pharmacokinetics lecture 12 Contents ...
Pharmacologic Principles
Therapeutic Drug Monitoring
Pharmacology KNH 413 Most Americans are not meeting RDA. Nutrient deficiencies worsen when medication is taken.
Pharmacology The science of Drugs.
Pharmacology KNH 413 Most Americans are not meeting RDA. Nutrient deficiencies worsen when medication is taken.
POLYPHARMACY.
Presentation transcript:

Connecting Pharmacology with Therapeutics Clive Roberts

Become wise!

What can be predicted from a drugs pharmacological profile Pharmacological actions Some adverse effects Some contraindications Some drug interactions Acute toxicity risk Mode of administration possibilities

What can NOT be predicted? Therapeutic effect Appropriate usage in comparison with other drugs Some adverse effects Some drug interactions

What does the pharmacological profile consist of Pharmacodynamic data Pharmacokinetic data Physicochemical properties Potential to induce or inhibit hepatic enzymes Acute toxicity information The therapeutic ratio Usage history Cost

Pharmacodynamic information What receptors does it block or stimulate Or what ionic channels or enzymes etc does it affect What is the hypersensitivity risk What unrelated toxicity occurs, how serious and how often What happens in acute overdose

Pharmacokinetic information How is it cleared from the blood – liver/kidney/lung etc First order / zero order process If liver, how high is the clearance rate What is the bioavailability If low is it due to pre-systemic hepatic clearance or poor absorption

Pharmacokinetic info. continued How is the drug distributed in the body What is the volume of distribution What is the extent of plasma protein binding What is the plasma half life

Patient groups at risk Liver disease Renal disease Heart disease Lung disease Elderly Those taking other drugs Pregnancy

So lets take the example of Phenytoin

?? Digoxin

Mrs Y.Y. Born 1912 Admitted late Feb with general deterioration in health, nausea, anorexia, constipation At her EPH there had been an outbreak of D+V 4 weeks previous. She had never really got better. Dehydrated, hypotensive, pale, slow reg pulse

Drugs – perindopril, digoxin, frusemide, aspirin, Isosorbide mononitrate Urea 31, creatinine 223 ECG ……………

Digoxin level 3.5 What went wrong?

What is it about the patient with hepatic failure that puts them at risk Pharmacokinetic disturbance - –Decreased clearance of some drugs –Increased bioavailability of some drugs –Altered distribution volume –Decreased protein binding CNS sensitivity Electrolyte abnormality

What is it about the patient with hepatic failure that puts them at risk - continued Fluid retention Risk of bleeding – generally and specifically in gut Metabolic disturbance Encephalopathy risk

And the renal patient ? Pharmacokinetic disturbance –Mainly affecting drug clearance –Also protein binding Increased sensitivity Poor tolerance of adverse effects Decreased effectiveness of some drugs

Drugs in the elderly Multiple indications leads to polypharmacy Pharmacokinetic disturbance of metabolism, excretion, protein binding and drug distribution Increased sensitivity to the actions of drugs on CVS, CNS, GIT Poor tolerance of adverse effect

Drug interaction Pharmacodynamic mechanisms usually easy to predict Pharmacokinetic mechanisms – need to know / look up.

Le Fin

Profile of new drug for reflux oesophagitis Phenothiazine drug with powerful antigastric secretory action at low doses. Acts on both h2 receptors and the proton pump Also blocks muscarinic receptors throughout the body Inhibits some hepatic enzymes Causes a rise in transaminases in some patients Limited experience in overdose

Profile of new drug for reflux oesophagitis High hepatic clearance with extraction ratio of 65% Widely distributed in tissues Plasma half life of 48 h

What might you predict about the adverse effects? Who might be at greatest risk? What drug interactions might occur? What about self harm doses?